FDA WARNING_LETTER - Argon Medical Productions & Vertrieb Gesellschaft MBH & CO - July 31, 2024

The FDA issued a Warning Letter to Argon Medical Productions & Vertrieb Gesellschaft MBH & CO on October 22, 2024, following an inspection from July 29-31, 2024, at their Bingen am-Rhein, Germany facility. The inspection revealed that the firm"s K3Pro dental implant systems were adulterated and misbranded, indicating non-conformity with regulatory requirements.

Key violations under the Quality System regulation (21 CFR Part 820) included a failure to adequately review, evaluate, and investigate complaints. Specifically, the firm did not investigate complaints involving osseointegration failures of their dental implants, contrary to their own complaint processing procedures. Argon Medical justified this by citing complex patient factors, treating these as returns rather than requiring a technical assessment. The FDA found their initial response inadequate, noting a lack of documented evidence or timelines for proposed corrective actions, such as procedure revisions and a retrospective review of past complaints.

Furthermore, the devices were misbranded due to significant violations of Medical Device Reporting (MDR) requirements (21 CFR Part 803). The firm failed to develop and implement adequate written MDR procedures for identifying, communicating, and timely transmitting reportable events. They also did not submit reports within 30 days for events, such as osseointegration failures, that reasonably suggested their devices caused or contributed to serious injury. The FDA recommended enrolling in the eMDR program and providing English translations of all revised procedures. The firm"s proposed corrective actions for MDR deficiencies, including updated procedures and staff training, were still in progress without sufficient documentation or timelines for the FDA to assess their adequacy.